Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:IPSC

Century Therapeutics Q3 2026 Earnings Date & Estimates

Century Therapeutics logo
$1.42 -0.04 (-2.74%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 0.00 (-0.35%)
As of 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Century Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 9, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Century Therapeutics in Q3 2026

Century Therapeutics is expected to post earnings of -$0.12 per share on revenue of $1.63 million. In the same quarter a year earlier Century Therapeutics reported -$0.32 per share. Century Therapeutics last reported on August 12, 2026, posting -$0.17 per share and missing the -$0.11 consensus estimate. Century Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.12
Expected Revenue
$1.63 million
Prior-Year EPS
-$0.32

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.17 (Missed by -$0.06)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Century Therapeutics Q3 2026 Earnings FAQ

Century Therapeutics (NASDAQ:IPSC) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Century Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Century Therapeutics to post earnings of -$0.12 per share for Q3 2026.

The consensus revenue estimate for Century Therapeutics is $1.63 million for Q3 2026.

Century Therapeutics Earnings Headlines

Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380698/0/en/century-therapeutics-to-attend-2026-jefferies-global-healthcare-conference-in-london.html
Century Therapeutics CNTY-813 Demonstrates Continued Advancement toward the Clinic Via Nonclinical Data Presented at EASD 2026
October 5, 2026  |  marketscreener.comM
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel
October 26 at 1:00 AM  |  Porter & Company (Ad)
Century Therapeutics, Inc. Presents Nonclinical Data For CNTY-813 At EASD
October 3, 2026  |  marketscreener.comM
Century Therapeutics Advances CNTY-813 Toward Clinical Testing With New EASD Data
October 2, 2026  |  rttnews.comhttps://www.rttnews.com/3696180/century-therapeutics-advances-cnty-813-toward-clinical-testing-with-new-easd-data.aspx
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373783/0/en/century-therapeutics-cnty-813-demonstrates-continued-advancement-toward-the-clinic-via-nonclinical-data-presented-at-easd-2026.html
See More Century Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email.

About Century Therapeutics

Century Therapeutics (NASDAQ:IPSC) is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells.

Century’s pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens. The company’s candidates are investigational and are being evaluated through preclinical and clinical research rather than marketed as approved treatments.

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics was established to advance iPSC-derived cell therapies using a platform intended to support standardized manufacturing and repeatable production. The company conducts research and clinical development primarily in the United States and works with collaborators and research organizations in the biotechnology and cell-therapy sectors.

View Century Therapeutics Profile
Earnings Tools